Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Upgraded by Wall Street Zen

Ventyx Biosciences (NASDAQ:VTYX) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently commented on the company. Piper Sandler cut Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price for the company. in a research note on Thursday, January 8th. Clear Str lowered Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 7th. Canaccord Genuity Group cut Ventyx Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $16.00 to $14.00 in a report on Thursday, January 8th. Oppenheimer lowered Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th. Finally, HC Wainwright cut Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 price objective for the company. in a report on Thursday, January 8th. Eight investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $14.00.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock opened at $14.00 on Friday. The firm has a 50 day simple moving average of $13.23 and a 200 day simple moving average of $8.49. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The firm has a market cap of $1.00 billion, a P/E ratio of -9.33 and a beta of 1.26.

Insider Buying and Selling at Ventyx Biosciences

In related news, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John Nuss sold 12,675 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This represents a 2.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 14.49% of the company’s stock.

Institutional Trading of Ventyx Biosciences

A number of large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ventyx Biosciences during the fourth quarter worth about $31,000. Hudson Bay Capital Management LP bought a new stake in Ventyx Biosciences in the 2nd quarter valued at approximately $34,000. Engineers Gate Manager LP acquired a new position in Ventyx Biosciences during the 2nd quarter worth approximately $42,000. Persistent Asset Partners Ltd acquired a new position in Ventyx Biosciences during the 3rd quarter worth approximately $51,000. Finally, Jump Financial LLC acquired a new position in Ventyx Biosciences during the 2nd quarter worth approximately $53,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.